

Amendments to the Specification:

Please replace paragraph [0001] with the following amended paragraph:

~~STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT~~

~~[0001] The work leading to the present invention was supported by one or more grants from the U.S. Government. The U.S. Government therefore has certain rights in the invention.~~

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims priority on prior U.S. Provisional Application S.N. 60/402,701, filed August 13, 2002, and which is incorporated herein in its entirety by reference.

Please replace paragraph [0002] with the following amended paragraph:

~~CROSS-REFERENCE TO RELATED APPLICATIONS~~

~~[0002] The present application claims priority on prior U.S. Provisional Application S.N. 60/402,701, filed August 13, 2002, and which is incorporated herein in its entirety by reference.~~

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT

[0002] The work leading to the present invention was supported by one or more grants from the U.S. Government. The U.S. Government therefore has certain rights in the invention.

Please add the following new paragraphs after paragraph [0007] on page 6:

[0007.1] Currently there are no diagnostic methods available in the market that can detect AD accurately and reliably. The only accurate method now available is by postmortem examination of the brain.

[0007.2] Nymox, Inc. has developed a test called AlzheimerAlert® that measures the amount of cerebrospinal fluid of a brain protein known as AD7C-NTP (neural thread protein) that is found in higher-than-normal concentrations in Alzheimer's patients. This urine test is considerably cheaper than any other test currently on the market, and the company claims over 90 percent accuracy. Even though the company received FDA clearance, it has experienced difficulty gaining industry acceptance (Medical DeviceLink 1997).

[0007.3] FMG Innovations, Inc. recently released the Early Alert Alzheimer's Home Screening Kit. This self-administered test uses 12 scent strips to screen patients. According to the company, a decrease in the sense of smell is one of the early indicators of AD (FMG Innovations 2001).

[0007.4] Neurochem, Inc. and Nycomed Amersham Imaging announced an agreement to develop a product for the diagnosis of Alzheimer's disease. The companies will use Neurochem's proprietary molecule as a basis, and work together to design a system that will detect the presence of amyloid plaques in the brain. It is anticipated that the successful completion of the project will result in a product capable of accurately detecting early-stage Alzheimer's disease (Market News Publishing Inc. 2001).

[0007.5] Currently, there are no drugs available in the market to stop the progression of Alzheimer's disease. The drugs that are being marketed are agents for symptomatic treatment and/or to slow the progression of the disease.

[0007.6] Antipsychotic agents are often used to treat some of the symptoms experienced by patients with senile dementia brought on by AD. The leading drugs in

this market are: tacrine (Cognex®) from Warner Lambert; donepezil (Aricept®) from Eisai (co-marketed by Pfizer), and galantamine HBr (Reminyl®), developed by Shire and to be marketed by Janssen Pharmaceutica Products, L.P. All three products can act as acetylcholinesterase inhibitors and are used to treat the memory/cognitive impairment that is often the earliest sign of AD.